Gexval Co., Ltd.
We implemented a third-party allotment capital increase.
~Toward accelerating development and adding pipeline additions in Australia~ ……
Gexval Co., Ltd. (President and CEO: Juran Kato, location: Fujisawa City, Kanagawa Prefecture), a drug discovery venture focused on the development of drugs to treat intractable and rare diseases*, has raised a total of approx. We would like to inform you that we have raised 450 million yen.
(English follows)
[Image 1
https://www.orpha.net/consor/cgi-bin/index.php- US NORD https://rarediseases.org/about/
– Japan Ministry of Health, Labor and Welfare, Orphan Drug Policy Page, Pharmaceutical and Medical Device Law Article 77-2
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html – Intractable Disease Information Center https://www.nanbyou.or.jp/ **: From PhRMA, 2022, A Decade of Innovation in Rare Diseases For inquiries regarding this matter:
Axil Capital https://www.axilcapital.com/inquiries
Mitsubishi UFJ Capital Planning Department 03-5205-8581
Oita Venture Capital 097-543-1919 (Telephone) 097-543-9191 (Fax) SMBC Venture Capital infovc@smbc-vc.co.jp
UTC Investment utc@utc.co.kr
Gexval Co., Ltd. info@gexval.com
GEXVal Completed the Close of New Funding Round with JPY 450 Million (USD 3 Million)
[Image 2
– Japan Ministry of Health, Labor and Welfare, Orphan Drug Policy Page, Pharmaceutical and Medical Device Law Article 77-2
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html – Intractable Disease Information Center https://www.nanbyou.or.jp/ **: From PhRMA, 2022, A Decade of Innovation in Rare Diseases For inquiries regarding this matter:
Axil Capital https://www.axilcapital.com/inquiries
Mitsubishi UFJ Capital Planning Department 03-5205-8581
Oita Venture Capital 097-543-1919 (Telephone) 097-543-9191 (Fax) SMBC Venture Capital infovc@smbc-vc.co.jp
UTC Investment utc@utc.co.kr
Gexval Co., Ltd. info@gexval.com
GEXVal Completed the Close of New Funding Round with JPY 450 Million (USD 3 Million)
[Image 2
This article was partly generated by AI. Some links may contain Ads. Press Release-Informed Article.